Comment 1). There has been some confusion in the literature about which PDE3 to call 3A and which to call 3B. The approved recommendations are listed below. However, please note at least one article ( J. Clin. Invest 95:1528-1538 (1995)), an older nomenclature that reverses this order has been used. In this publication PDE3B refers to the PDE with GB ACC# M91667 and not Z22867. The committee has received a number of questions regarding this issue. This descrepancy occurred because of a lack of communication between the authors of the paper and the PDE nomenclature group. We hope to avoid as much as possible this type of situation in the future and encourage prospective authors to check with any members of the nomenclature committee for clarification if they feel that it might be necessary. An erratum from the authors changing the nomenclature to that listed below has recently been publshed (J. Clin. Invest 99:551 (1997)). It is the understanding of the committee that the nomenclature listed here will be used in future publications. The nomenclature committee very much appreciates the cooperation of the authors in changing their names to conform to the recommenedations listed here.

The committee requests that all new manuscripts use PDE3A for the major PDE3 present in most platelet and smooth muscle preparations (ie those with the sequence identical or nearly identical to that in GB ACC# M91667) and PDE3B for the PDE3 isoform present in adipose tissue, beta cells, etc that have the same sequence as that listed in GB ACC# Z22867.